Passage Bio, Inc.
PASG
$4.94
$0.091.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 43.58% | -2.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.05% | -14.12% | |||
| Operating Income | -15.05% | 14.12% | |||
| Income Before Tax | -3.47% | 41.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.47% | 41.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.47% | 41.78% | |||
| EBIT | -15.05% | 14.12% | |||
| EBITDA | -16.46% | 13.89% | |||
| EPS Basic | -3.37% | 42.25% | |||
| Normalized Basic EPS | -19.09% | 14.25% | |||
| EPS Diluted | -3.37% | 42.25% | |||
| Normalized Diluted EPS | -19.09% | 14.25% | |||
| Average Basic Shares Outstanding | 0.09% | 0.82% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||